{"transactions":[{"id":765689,"issuer":{"id":3757,"kind":"organization","name":"Andersen Group Inc."},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-05-22T20:23:46.000Z","date":"2026-05-20","kind":"purchase","planned":false,"acquired":true,"shares":2367,"price":35.82,"value":84785.94,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001193125-26-236973","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302450/000119312526236973/ownership.xml","form_type":"4"}},{"id":960808,"issuer":{"id":3757,"kind":"organization","name":"Andersen Group Inc."},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-12-22T21:10:41.000Z","date":"2025-12-18","kind":"purchase","planned":false,"acquired":true,"shares":12633,"price":16,"value":202128.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of Class A common stock were purchased by the Reporting Person through a directed share program in connection with the Issuer's initial public offering of Class A common stock."}],"balance_after":12633,"source":{"system":"sec-edgar","filing":"0001193125-25-328741","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302450/000119312525328741/ownership.xml","form_type":"4"}},{"id":2735732,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2021-04-29T22:12:54.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":6000,"derivative":{"exercise_price":20.35,"expiration_date":"2031-04-26","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001179110-21-004698","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1302450/000117911021004698/edgar.xml","form_type":"4"}},{"id":2735731,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-29T22:12:54.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":9828,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":68093,"source":{"system":"sec-edgar","filing":"0001179110-21-004698","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302450/000117911021004698/edgar.xml","form_type":"4"}},{"id":3166387,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2020-04-30T22:53:45.000Z","date":"2020-04-28","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":6000,"derivative":{"exercise_price":30.14,"expiration_date":"2030-04-27","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001179110-20-005297","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1302450/000117911020005297/edgar.xml","form_type":"4"}},{"id":3166386,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-04-30T22:53:45.000Z","date":"2020-04-28","kind":"grant","acquired":true,"shares":6635,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":58265,"source":{"system":"sec-edgar","filing":"0001179110-20-005297","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302450/000117911020005297/edgar.xml","form_type":"4"}},{"id":3542199,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2019-05-02T22:17:15.000Z","date":"2019-04-30","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":6000,"derivative":{"exercise_price":23.85,"expiration_date":"2029-04-29","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001179110-19-005455","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1302450/000117911019005455/edgar.xml","form_type":"4"}},{"id":3542198,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-02T22:17:15.000Z","date":"2019-04-30","kind":"grant","acquired":true,"shares":8385,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":51630,"source":{"system":"sec-edgar","filing":"0001179110-19-005455","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302450/000117911019005455/edgar.xml","form_type":"4"}},{"id":3947258,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2018-05-03T22:13:03.000Z","date":"2018-05-01","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":6000,"derivative":{"exercise_price":24.43,"expiration_date":"2028-04-30","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001179110-18-006189","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1302450/000117911018006189/edgar.xml","form_type":"4"}},{"id":3947257,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-03T22:13:03.000Z","date":"2018-05-01","kind":"grant","acquired":true,"shares":8186,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":43245,"source":{"system":"sec-edgar","filing":"0001179110-18-006189","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302450/000117911018006189/edgar.xml","form_type":"4"}},{"id":4313391,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2017-05-18T22:02:53.000Z","date":"2017-05-17","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":35059,"source":{"system":"sec-edgar","filing":"0001179110-17-007539","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302450/000117911017007539/edgar.xml","form_type":"4"}},{"id":4574979,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-25T16:34:01.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":10000,"price":11.38,"value":113800.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (3) above."}],"balance_after":0,"derivative":{"exercise_price":9.62,"expiration_date":"2026-05-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-16-151947","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151947/a4.xml","form_type":"4"}},{"id":4574978,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-25T16:34:01.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":10000,"price":8.57,"value":85700.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option, which provided for vesting in three equal annual installments following May 28, 2015, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (3) above."}],"balance_after":0,"derivative":{"exercise_price":12.43,"expiration_date":"2025-05-27","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-16-151947","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151947/a4.xml","form_type":"4"}},{"id":4574977,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-25T16:34:01.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":17000,"price":13,"value":221000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (3) above."}],"balance_after":0,"derivative":{"exercise_price":8,"expiration_date":"2024-09-23","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001104659-16-151947","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151947/a4.xml","form_type":"4"}},{"id":4574976,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-25T16:34:01.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":9091,"price":15.71,"value":142819.61,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (3) above."}],"balance_after":0,"derivative":{"exercise_price":5.29,"expiration_date":"2024-06-04","underlying":"Common Stock","underlying_shares":9091},"source":{"system":"sec-edgar","filing":"0001104659-16-151947","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151947/a4.xml","form_type":"4"}},{"id":4574975,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-25T16:34:01.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":5434,"price":17.09,"value":92867.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (3) above."}],"balance_after":0,"derivative":{"exercise_price":3.91,"expiration_date":"2018-05-27","underlying":"Common Stock","underlying_shares":5434},"source":{"system":"sec-edgar","filing":"0001104659-16-151947","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151947/a4.xml","form_type":"4"}},{"id":4574974,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-25T16:34:01.000Z","date":"2016-10-24","kind":"other","acquired":false,"shares":15830,"price":21,"value":332430.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc.  (\"Parent\") and Augusta Merger Sub, Inc. (\"Merger Sub\"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the \"Offer\") to purchase each outstanding share of the Company's Common Stock for $21.00 per share (the \"Offer Price\"), without any interest and subject to any tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at 12:00 midnight, New York City time, at the end of October 24, 2016, Merger Subsidiary accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-16-151947","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151947/a4.xml","form_type":"4"}},{"id":4574973,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":44673,"kind":"person","name":"Gunderson Robert V JR","position":1,"cik":"0001302450","reported_name":"Gunderson Robert V JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-25T16:34:01.000Z","date":"2016-10-24","kind":"other","acquired":false,"shares":11002,"price":21,"value":231042.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc.  (\"Parent\") and Augusta Merger Sub, Inc. (\"Merger Sub\"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the \"Offer\") to purchase each outstanding share of the Company's Common Stock for $21.00 per share (the \"Offer Price\"), without any interest and subject to any tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at 12:00 midnight, New York City time, at the end of October 24, 2016, Merger Subsidiary accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned by G&H Partners. Mr. Gunderson is a general partner of G&H Partners, and as such he may be deemed to share voting and dispositive power with respect to the shares held by G&H Partners. Mr. Gunderson disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-16-151947","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151947/a4.xml","form_type":"4"}}]}